


To achieve capital growth and income from a portfolio of predominantly UK equities
| Name | % Net Assets |
|---|---|
| Royal Dutch Shell PLC | 8.7% |
| GlaxoSmithKline PLC | 6.3% |
| Vodafone Group PLC | 5.9% |
| BG Group PLC | 4.4% |
| AstraZeneca PLC | 4.4% |
| British American Tobacco PLC | 4.0% |
| Unilever PLC | 3.1% |
| Cadbury PLC | 2.8% |
| BP PLC | 2.8% |
| Centrica PLC | 2.7% |
| Key | % Net Assets |
|---|---|
| 8.7% | |
| 6.3% | |
| 5.9% | |
| 4.4% | |
| 74.7% |
| Date | 02-Oct-2023 |
|---|---|
| NAV | 313.04p |
| Currency | GBP |
| Change | -3.66p |
| % | -1.16% |
| YTD change | 313.04p |
| YTD % | n/a |
| Fund Inception | 01/05/1985 |
|---|---|
| Fund Manager | Glen Pratt |
| TER | 1.04 (30-Dec-2011) |
| Minimum Investment | |
|---|---|
| Initial | n/a |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 4.00% |
| Annual Mang't | 1.00% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.02 |
| Sharpe ratio | 0.06 |
You are here: research